A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX¿147 in Adults With APOL1-dependent Focal Segmental Glomerulosclerosis
Clinical Trial Grant
Administered By
Medicine, Nephrology
Awarded By
Vertex Pharmaceuticals Inc.
Start Date
June 4, 2020
End Date
September 30, 2022
Administered By
Medicine, Nephrology
Awarded By
Vertex Pharmaceuticals Inc.
Start Date
June 4, 2020
End Date
September 30, 2022